Wadden, T. et al. 2022. LIRAGLUTIDE 3.0 mg AS AN ADJUNCT TO INTENSIVE BEHAVIOR THERAPY IN INDIVIDUALS WITH OBESITY: SCALE IBT 56-WEEK RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED TRIAL. Journal of the ASEAN Federation of Endocrine Societies. 34, 2 (May 2022), 9–10.